WIT DYNE(SZ:000915) Bei Jing Shang Bao·2025-06-19 12:29Core Viewpoint - Huate Dain (000915), focused on pediatric medication, has received a stake increase from prominent investor Guo Weisong, indicating confidence in the company's future prospects [1][3]. Group 1: Shareholding Changes - On June 17, Guo Weisong increased his stake in Huate Dain by purchasing 24,400 shares at an average price of 29.19 CNY per share, raising his total holdings to 11.7166 million shares, which constitutes 5% of the company's total share capital [1][3]. - Guo Weisong has a history of building positions in companies through private placements and has been a significant shareholder in Huate Dain since early 2024, when he held 9.2865 million shares (3.96%) [3][4]. Group 2: Financial Performance - In 2024, Huate Dain reported a revenue of approximately 2.134 billion CNY, a year-on-year decrease of 14.08%, and a net profit of about 516 million CNY, down 11.9% [5]. - In the first quarter of 2024, the company achieved a revenue of approximately 616 million CNY, reflecting a year-on-year growth of 7.78%, with a net profit of 182 million CNY, up 8.13% [6]. Group 3: Business Focus - Huate Dain's primary revenue and profit sources come from its subsidiary, Dain Pharmaceutical, which specializes in the research, production, and marketing of pediatric medications and health-related products [4]. - The main pediatric products include Yikexin, YDxin, Dain Iron, Dain Calcium, Dain Zinc, and various other medications aimed at children's health [4].